Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease-Reference-Cited by-同舟云学术

Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease

Published:2018-10-16 Issue:3 Volume:10 Page:255-260
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Panarese Joseph D.¹²,Engers Darren W.¹²,Wu Yong-Jin³^ORCID,Bronson Joanne J.³,Macor John E.³,Chun Aspen¹²,Rodriguez Alice L.¹²,Felts Andrew S.¹²,Engers Julie L.¹²,Loch Matthew T.¹²,Emmitte Kyle A.¹²^ORCID,Castelhano Arlindo L.⁴,Kates Michael J.⁴,Nader Michael A.⁵,Jones Carrie K.¹²⁶,Blobaum Anna L.¹²,Conn P. Jeffrey¹²⁶,Niswender Colleen M.¹²⁶,Hopkins Corey R.¹²^ORCID,Lindsley Craig W.¹²^ORCID

Affiliation:

1. Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States

2. Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States

3. Bristol-Myers Squibb Co., Research & Development, 5 Research Parkway, Wallingford, Connecticut 06492 United States

4. Davos Pharma, A Davos Chemical Company, 600 East Crescent Ave., Upper Saddle River, New Jersey 07458, United States

5. Center for the Neurobiology of Addiction Treatment, Wake Forest School of Medicine, Medical Center Boulevard Winston-Salem, North Carolina 27157, United States

6. Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

Funder

National Institutes of Health

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.8b00426

Reference33 articles.

1. Epidemiology of Parkinson’s disease

2. Preventing and controlling dyskinesia in Parkinson's disease-A view of current knowledge and future opportunities